KPV
A tripeptide (Lysine-Proline-Valine) derived from alpha-MSH with potent anti-inflammatory and antimicrobial properties.
Common Dosage
Oral, Topical, or Injectable protocols vary
Category
Anti-inflammatory
- Gut health (IBD)
- Anti-microbial
- Skin inflammation
KPV (Lys-Pro-Val) is the C-terminal tripeptide of alpha-melanocyte stimulating hormone (α-MSH) and carries much of the anti-inflammatory activity of the full peptide. Research on α-MSH's immunomodulatory properties in the 1990s–2000s identified KPV as the minimal active sequence responsible for its anti-inflammatory effects — without the tanning or hormonal effects of the full molecule. This has made KPV valuable as a targeted anti-inflammatory tool.
KPV inhibits pro-inflammatory cytokines including IL-1β, IL-6, and TNF-α by interacting with melanocortin receptors (particularly MC1R and MC3R) on immune cells. It also directly inhibits NF-κB nuclear translocation — a master switch for inflammatory gene expression. In the gut, oral KPV can penetrate intestinal epithelial cells and interact with intracellular inflammatory pathways, making it particularly effective for intestinal inflammation.
- Inflammatory bowel disease (IBD) — Crohn's and ulcerative colitis
- Skin inflammatory conditions — atopic dermatitis, psoriasis
- Gut barrier function restoration
- Wound healing acceleration
- Antimicrobial applications — active against bacteria and fungi
- Systemic anti-inflammatory protocols
IBD Animal Models
Oral KPV has shown dramatic reduction in colitis severity in animal models — including reduced histological damage, improved mucosal integrity, and normalized inflammatory cytokine profiles. Its ability to work orally (surviving gut enzymatic degradation and penetrating epithelial cells) makes it unique among anti-inflammatory peptides.
Combined with BPC-157
Practitioners using KPV alongside BPC-157 for gut healing report synergistic outcomes — KPV controlling the inflammatory environment while BPC-157 drives tissue repair and vascular remodeling. This combination addresses both the inflammatory and structural aspects of IBD.
- Human clinical trial data is limited compared to animal model evidence
- Melanocortin receptor modulation across all MCR subtypes carries potential hormonal effects
- Oral vs. injectable bioavailability and optimal delivery are not fully established in humans
- Autoimmune conditions involving innate immune system suppression may have complex interactions
- None reported commonly